Henlius’ Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC
2 min read
Shanghai Henlius Biotech, Inc. (2696. HK) announced that the new drug application (NDA) for new indication of...